Alogriptin versus Standard Therapy on Diastolic Dysfunction in Type2 Diabetes Mellitus-Juntendo

Alogriptin versus Standard Therapy on Diastolic Dysfunction in Type2 Diabetes Mellitus-Juntendo - ADAM-J study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008162

Enrollment

100

Registered

2012-06-15

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paitients with type2 diabetes mellitus

Interventions

Additional therapy of Alogriptin(DPP-4 antagonist) for patinets with type2 diabetes mellitus. The patients with standard therapy at least for three months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type2 diabetes mellitus who meet our criteria of LV ejection fraction of more than 50% E/e' of more than 15 or e' of less than 8, and blood pressure under 140/90mmHg.

Exclusion criteria

Exclusion criteria: Exclusion criteria are type1 diabetes mellitus, chronic kidney disease(male; creatinine level > 1.4, female; creatinine level > 1.2), severe liver dysfunction, chronic heart failure(NYHA functional class > 3), valvular heart disease, atrial fibrillation, uncontroled arrythmia, old myocardial infarction within three months.

Design outcomes

Primary

Measure	Time frame
Diastolic function assessed by echocardiography	—

Countries

Japan

Contacts

Public ContactMasao Daimon

Juntendo University Department of Cardiology

masaodaimon@gmail.com03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026